Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Cancer Immunology, Immunotherapy : CII|August 7, 2023
Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactionsKoki Uehara, Kenro Tanoue, Kyoko Yamaguchi, et al.
World Journal of Clinical Cases|September 26, 2022
Obligate aerobic, gram-positive, weak acid-fast, nonmotile bacilli, <i>Tsukamurella tyrosinosolvens</i>: Minireview of a rare opportunistic pathogenDaisuke Usuda, Risa Tanaka, Makoto Suzuki, et al.
Cancer Science|September 7, 2018
PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancerMichitaka Nakano, Mamoru Ito, Risa Tanaka, et al.
Journal of Medical Cases|July 15, 2022
ST-Elevation Acute Myocardial Infarction in a Young ManDaisuke Usuda, Risa Tanaka, Makoto Suzuki, et al.
Scientific Reports|February 3, 2021
Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumabKenro Tanoue, Shingo Tamura, Hitoshi Kusaba, et al.
Anti-Cancer Drugs|September 15, 2017
Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancerMamoru Ito, Hitoshi Kusaba, Satomi Mukaide, et al.
Anticancer Research|May 7, 2017
Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric CancerKyoko Inadomi, Hitoshi Kusaba, Yuzo Matsushita, et al.
Juntendo Iji Zasshi = Juntendo Medical Journal|November 15, 2024
Evaluation of Difference in Emergency Care Quality by Years of Physician Experience at the Emergency DepartmentShungo Tokunaga, A I Ikeda, Daisuke Usuda, et al.
Anticancer Research|January 30, 2022
Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland CarcinomaKazuki Hashimoto, Ryuji Yasumatsu, Ryosuke Kuga, et al.
In Vivo (Athens, Greece)|March 4, 2022
Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland CancerTakafumi Nakano, Ryuji Yasumatsu, Kazuki Hashimoto, et al.
Pageof 8